All AbMole products are for research use only, cannot be used for human consumption.
H-89 dihydrochloride is an inhibitor of PKA and MSK, inhibits cyclic-AMP response element binding protein-mediated MAPK phosphatase-1 induction by lipopolysaccharide. The Ki value is 48 nM for PKA inhibitor. H-89 having a relatively large number of PKA-independent effects which may seriously compromise interpretation of data, and it also inhibits at least 8 other kinases. H-89 significantly inhibits the forskolin-induced neurite outgrowth from PC12D cells.
H-89 (30 μM) inhibits significantly cAMP-dependent histone IIb phosphorylation activity in PC12D cell lysates. H-89 (1-2 μM) significantly slows the repriming rate in rat skinned fibres, most likely due to it deleteriously affecting the T-system potential.
H-89 (0.2 mg/100g, i.p.) significantly increases seizure latency and threshold in PTZ-treated animals. H-89 (0.05, 0.2 mg/100 g, i.p.) prevents the epileptogenic activity of bucladesine (300 nM) with significant increase of seizure latency and seizure threshold.
| Cell Experiment | |
|---|---|
| Cell lines | Hela cells |
| Preparation method | Choline uptake. Choline uptake was measured as described.Briefly. cells grown on colleen-coated plastic sheets, were preincubated for 30 min with medium containing H-89 or no supplements ascontrol, After preincubation, cells were immersed in medium with or without H-89, containing choline(5μCi/ml), After different times, cells were washed throughly with 58mmol/l choline chloride in PBS. Finally, uptake and incorpration of [H] choline were determined by liquid scintillation counting. background radioactivity was measured by repeating the experiment at 4℃. |
| Concentrations | 0~100μM |
| Incubation time | 1 h |
| Animal Experiment | |
|---|---|
| Animal models | Adult male Sprague-Dawley rats model |
| Formulation | 5% DMSO in 0.9% sterile saline |
| Dosages | 20 mg/kg or 200mg/kg twice daily |
| Administration | oral gavage |
| Molecular Weight | 519.28 |
| Formula | C20H20BrN3O2S.2HCl |
| CAS Number | 130964-39-5 |
| Solubility (25°C) | DMSO 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Lochner et al. Cardiovasc Drug Rev. The many faces of H89: a review.
| Related PKA Products |
|---|
| 8-CPT-Cyclic AMP sodium
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). |
| PKA-IN-1
PKA-IN-1 is a potent and selective cyclic AMP-dependent protein kinase (PKA) catalytic subunit (cAK) inhibitor with an IC50 of 0.03 μM. |
| Sp-8-CPT-cAMPS
Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). |
| 6-Bnz-cAMP sodium salt
6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. |
| CW 008
CW 008 is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
